The generic brand eszopiclone was previously marketed by Sepracor Inc. as the brand name Estorra. Sepracor will now distribute this drug as Lunesta; and of particular note, the drug has now received approval to be prescribed without the recommendation that use be limited to less than two weeks.
"This novel non-benzodiazepine sleep aid provides a new option for the millions of Americans with chronic insomnia. Unlike all other available prescription sleep aids, which are generally indicated for short-term use, eszopiclone has been studied and approved for use when longer-term treatment is needed,’ said Andrew Krystal, M.D., Director of the Sleep Disorder Research Laboratory and Insomnia Program at Duke University Medical Center, Durham, NC” (PR Newswire).
